Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental amyotrophic lateral sclerosis drug after a mid-stage study failed to meet its goals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.